DE69518406T2 - Monoklonale antikörper gegen den tie-rezeptor und deren verwendung - Google Patents

Monoklonale antikörper gegen den tie-rezeptor und deren verwendung

Info

Publication number
DE69518406T2
DE69518406T2 DE69518406T DE69518406T DE69518406T2 DE 69518406 T2 DE69518406 T2 DE 69518406T2 DE 69518406 T DE69518406 T DE 69518406T DE 69518406 T DE69518406 T DE 69518406T DE 69518406 T2 DE69518406 T2 DE 69518406T2
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
antibodies against
tie receptor
useful
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69518406T
Other languages
English (en)
Other versions
DE69518406D1 (de
Inventor
Kari Alitalo
Marja-Terttu Matikainen
Paeivi Karnani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Licentia Oy
Original Assignee
MATIKAINEN MARJA TERTTU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MATIKAINEN MARJA TERTTU filed Critical MATIKAINEN MARJA TERTTU
Publication of DE69518406D1 publication Critical patent/DE69518406D1/de
Application granted granted Critical
Publication of DE69518406T2 publication Critical patent/DE69518406T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69518406T 1994-03-29 1995-03-29 Monoklonale antikörper gegen den tie-rezeptor und deren verwendung Expired - Lifetime DE69518406T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/220,240 US5955291A (en) 1992-01-09 1994-03-29 Antibodies recognizing tie receptor tyrosine kinase and uses thereof
PCT/FI1995/000170 WO1995026364A1 (en) 1994-03-29 1995-03-29 Monoclonal antibodies recognizing tie-receptor and their use

Publications (2)

Publication Number Publication Date
DE69518406D1 DE69518406D1 (de) 2000-09-21
DE69518406T2 true DE69518406T2 (de) 2001-03-15

Family

ID=22822698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69518406T Expired - Lifetime DE69518406T2 (de) 1994-03-29 1995-03-29 Monoklonale antikörper gegen den tie-rezeptor und deren verwendung

Country Status (13)

Country Link
US (1) US5955291A (de)
EP (1) EP0753015B1 (de)
JP (1) JP3683270B2 (de)
AT (1) ATE195533T1 (de)
AU (1) AU697185B2 (de)
CA (1) CA2185043C (de)
DE (1) DE69518406T2 (de)
DK (1) DK0753015T3 (de)
ES (1) ES2151595T3 (de)
MX (1) MX9604391A (de)
NO (1) NO319586B1 (de)
NZ (1) NZ283366A (de)
WO (1) WO1995026364A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
EP0821728B1 (de) 1995-04-06 2004-08-11 Regeneron Pharmaceuticals, Inc. Tie-2 liganden, herstellungsverfahren und verwendung
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7063965B2 (en) 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
WO2000075323A1 (en) * 1999-06-07 2000-12-14 Immunex Corporation Tek antagonists
US6521424B2 (en) * 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
DE60131146T2 (de) 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
AU2001244509A1 (en) * 2000-03-30 2001-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treatment of conditions involving obstruction of blood flow
WO2002036771A2 (en) 2000-11-06 2002-05-10 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1519956B1 (de) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoklonale antikörper und deren anwendungsverfahren
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
SI1458853T1 (sl) * 2002-05-16 2010-04-30 Absorber Ab Postopki donorsko specifiŽŤnega navzkriĹľnega ujemanja
EP1565491B1 (de) 2002-11-20 2010-03-31 Cancer Research Technology Limited An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese
JP2006523240A (ja) * 2003-04-11 2006-10-12 メディミューン，インコーポレーテッド ＥｐｈＡ２、低増殖性細胞障害ならびに上皮および内皮の再構成
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
EP1479760A1 (de) * 2003-05-19 2004-11-24 ProBioGen AG Künstliches Immunorgan
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7348001B2 (en) * 2003-08-12 2008-03-25 Dyax Corp. Tie1-binding ligands
ES2364147T3 (es) * 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. Polipéptidos de fusión capaces de activar receptores.
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
ATE481477T1 (de) * 2004-03-09 2010-10-15 Absorber Ab Endothelvorläuferzellen und verfahren zur verwendung davon
CA2576886A1 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US9896933B1 (en) 2011-02-07 2018-02-20 Ameriband, Llc Continuously variable displacement engine
US9540932B1 (en) 2011-02-07 2017-01-10 Ameriband, Llc Continuously variable displacement engine
US10041405B1 (en) 2011-02-07 2018-08-07 Ameriband, Llc Continuously variable displacement engine
US9109446B1 (en) 2011-02-07 2015-08-18 Ameriband, Llc Continuously variable displacement engine
US9581057B1 (en) 2014-08-20 2017-02-28 Ameriband, Llc Valve actuator system capable of operating multiple valves with a single cam

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620826A1 (de) * 1992-01-09 1994-10-26 Helsinki University Holding, Ltd. Tie, eine neuartiger tyrosinkinase-rezeptor in endothelzellen
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof

Also Published As

Publication number Publication date
NO964013L (no) 1996-09-24
EP0753015B1 (de) 2000-08-16
NZ283366A (en) 1998-04-27
US5955291A (en) 1999-09-21
DK0753015T3 (da) 2000-11-13
EP0753015A1 (de) 1997-01-15
JPH09511141A (ja) 1997-11-11
AU2139295A (en) 1995-10-17
WO1995026364A1 (en) 1995-10-05
DE69518406D1 (de) 2000-09-21
NO964013D0 (no) 1996-09-24
CA2185043C (en) 2008-03-18
NO319586B1 (no) 2005-08-29
CA2185043A1 (en) 1995-10-05
ES2151595T3 (es) 2001-01-01
JP3683270B2 (ja) 2005-08-17
ATE195533T1 (de) 2000-09-15
MX9604391A (es) 1997-07-31
AU697185B2 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
DE69518406D1 (de) Monoklonale antikörper gegen den tie-rezeptor und deren verwendung
ATE108666T1 (de) Ultraschall-kontrastmittel, verfahren zu ihrer herstellung und verwendung derselben als diagnostika und therapeutika.
ATE110172T1 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
ATE388167T1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
NL300985I2 (en) mogamulizumab
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
DE69334158D1 (de) Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
DE69334259D1 (de) Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierungs-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyten beschränkt ist, für die Behandlung von B-Zell-Lymphoma
ATE301676T1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
DE60128452D1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
ES2121881T3 (es) Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DE59310204D1 (de) Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie
ES2149155T3 (es) Peptidos sinteticos que contienen secuencias de factor viia y su utilizacion.
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
李斯德 et al. STUDY OF RADIOIMMUNOIMAGING WITH MONOCLONAL ANTIBODY AGAINST THE PATIENTS WITH SCLC
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LICENTIA LTD., HELSINKI, FI

8381 Inventor (new situation)

Inventor name: ALITALO, KARI, ESPOO, FI

Inventor name: MATIKAINEN, MARJA-TERTTU, MYNÄMÄKI, FI

Inventor name: KARNANI, PÄIVI, TURKU, FI